These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38645565)

  • 1. Microenvironment, systemic inflammatory response and tumor markers considering consensus molecular subtypes of colorectal cancer.
    Jakab A; Patai ÁV; Darvas M; Tormássi-Bély K; Micsik T
    Pathol Oncol Res; 2024; 30():1611574. PubMed ID: 38645565
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
    Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
    PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
    Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer.
    Sandberg TP; Stuart MPME; Oosting J; Tollenaar RAEM; Sier CFM; Mesker WE
    BMC Cancer; 2019 Mar; 19(1):284. PubMed ID: 30922247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
    Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutation status and consensus molecular subtypes of colorectal cancer in patients from Rwanda.
    Nzitakera A; Uwamariya D; Kato H; Surwumwe JB; Mbonigaba A; Ndoricyimpaye EL; Uwamungu S; Manirakiza F; Ndayisaba MC; Ntakirutimana G; Seminega B; Dusabejambo V; Rutaganda E; Kamali P; Ngabonziza F; Ishikawa R; Watanabe H; Rugwizangoga B; Baba S; Yamada H; Yoshimura K; Sakai Y; Sugimura H; Shinmura K
    BMC Cancer; 2024 Oct; 24(1):1266. PubMed ID: 39394554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An inflammation-related subtype classification for analyzing tumor microenvironment and clinical prognosis in colorectal cancer.
    Pei J; Gao Y; Wu A
    Front Immunol; 2024; 15():1369726. PubMed ID: 38742117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer.
    Park JH; McMillan DC; Powell AG; Richards CH; Horgan PG; Edwards J; Roxburgh CS
    Clin Cancer Res; 2015 Feb; 21(4):882-8. PubMed ID: 25473000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.
    Rebersek M
    Radiol Oncol; 2020 May; 54(3):272-277. PubMed ID: 32463385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
    Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
    Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host-microbiota interactions contributing to the heterogeneous tumor microenvironment in colorectal cancer.
    Li X; Wu D; Li Q; Gu J; Gao W; Zhu X; Yin W; Zhu R; Zhu L; Jiao N
    Physiol Genomics; 2024 Feb; 56(2):221-234. PubMed ID: 38073489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
    Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
    Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer.
    Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Yamazoe A; Kimura K; Toyokawa T; Amano R; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
    Anticancer Res; 2015 Sep; 35(9):5037-46. PubMed ID: 26254405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral Budding in Pretreatment Biopsies, among Tumor Microenvironmental Components, Can Predict Prognosis and Neoadjuvant Therapy Response in Colorectal Adenocarcinoma.
    Yim K; Jang WM; Cho U; Sun S; Chong Y; Seo KJ
    Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888645
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
    Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
    Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
    Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation-based prognostic scores as indicators to select candidates for primary site resection followed by multimodal therapy among colorectal cancer patients with multiple metastases.
    Shimura T; Toiyama Y; Saigusa S; Imaoka H; Okigami M; Fujikawa H; Hiro J; Kobayashi M; Ohi M; Araki T; Inoue Y; Uchida K; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2017 Aug; 22(4):758-766. PubMed ID: 28299463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.